World Medical Innovation Forum

Biogen CEO rehashes old ALS clinical trial: “It was the single-most negative trial I’ve ever seen.”

Biogen‘s made headlines of late for committing $2.5 billion on a Alzheimer’s drug development gamble – and, notably, preparing for a return to the ALS market. Making such broad commitments can stir a lot of hope up among a desperate patient base – something CEO George Scangos has learned a lesson or two about by now. Two years ago, Biogen famously halted Phase 3 […]

Devices & Diagnostics

Brain prosthetics? Neuromodulation? The ‘disruptive dozen’ techs that’ll accelerate neuropsychiatric care

Partners Healthcare just released a list of what it ranks the top dozen most promising approaches in neurocare. Here’s that dozen, populated with useful links that inform the direction academia – and business – are headed. They’ve been vetted, and it’s confirmed: These trends truly are on the bleeding edge of research. Many of these applications […]